Intuitive delivered a strong Q1 2026 with 17% procedure growth driven by broad-based adoption of da Vinci and Ion systems, despite ongoing challenges in China and Japan.

• Total procedures grew 17%, with da Vinci procedures up 16% to 847,000 and Ion procedures jumping 39% to 43,000, supported by increased utilization in key markets.
• U.S. da Vinci procedures advanced 14%, led by general surgery, with overall utilization growth of 4%; international procedures increased by 19%, despite headwinds in China and Japan.
• Da Vinci 5 system placements and clinical adoption remain encouraging; FDA clearance for Force Feedback instruments supports expanding digital and tactile capabilities.
• Single Port (SP) procedures surged 68%, driven by expansion in Korea, the U.S., and international markets, with upcoming product integrations poised to enhance long-term growth.
• Ion's pipeline progress includes advancements in early malignancy detection, highlighted by recent Mayo Clinic data emphasizing its role in improving lung cancer survival.